Antimicrobial Therapy Efficacy in Bloodstream Infections

Bloodstream infections, or bacteraemias, remain a leading cause of morbidity and mortality worldwide. The efficacy of antimicrobial therapy in this context hinges on several interrelated factors: the promptness of administration, the appropriateness of the chosen agent to the causative pathogen, and the control of infection sources. Early empirical therapy must balance broad‐spectrum coverage to reduce the risk of undertreatment against the long‐term consequences of driving resistance. Delays in appropriate treatment have been consistently linked to higher mortality and slower resolution of fever, emphasising the critical importance of time-to-therapy metrics. Concurrently, burgeoning resistance mechanisms—such as extended‐spectrum β-lactamases and carbapenemases—threaten the utility of many first-line agents, necessitating rapid diagnostic methods and predictive models to guide therapy. Mathematical and simulation modelling contributes to understanding the trade-offs between narrow- and broad-spectrum regimens, informing stewardship efforts to preserve antimicrobial efficacy. Advances in rapid molecular diagnostics, clinical risk scores and predictive analytics are converging to enable more targeted initial therapy, potentially reducing both overtreatment and the emergence of resistance. The global challenge of bloodstream infections calls for integrated strategies that combine timely, evidence-based empirical treatment, rigorous source control and adaptive stewardship programmes to optimise patient outcomes and curb the spread of resistance.

Research from Nature Portfolio

Modelling work using a deterministic state-transition framework has explored the feasibility of shifting empirical treatment of Escherichia coli bacteraemia from broad- to narrow-spectrum antibiotics over a five-year horizon. Three treatment scenarios of increasing spectrum were compared in terms of mortality, antibiotic usage and emergence of resistance. The study predicts that narrower-spectrum regimens can reduce reliance on second- and third-line agents but may increase resistance to first-line drugs and slightly raise mortality unless treatment duration is shortened and baseline outcomes improved. The flexible model offers a quantitative tool for tailoring stewardship strategies across varying clinical settings.

Antimicrobial Therapy Efficacy in Bloodstream Infections publication trend

The graph below shows the total number of articles in antimicrobial therapy efficacy in bloodstream infections across all publications each year (not limited to Nature Index journals).

Technical terms

Bacteraemia: Presence of viable bacteria in the bloodstream, often leading to systemic inflammation and sepsis.

Empirical antimicrobial therapy: Initial antibiotic treatment commenced before definitive pathogen identification or susceptibility results are available.

Defervescence: Reduction of body temperature to normal levels, used as a clinical marker of infection resolution.

Extended-spectrum β-lactamase (ESBL): Enzymes produced by certain bacteria that confer resistance to penicillins and cephalosporins.

Spectrum of antibiotic activity: Range of bacterial species against which an antimicrobial agent is effective, described as narrow or broad.

Source control: Procedures undertaken to eliminate the origin of infection, such as drainage of abscesses or removal of infected devices.

References

1. Prompt antimicrobial therapy and source control on survival and defervescence of adults with bacteraemia in the emergency department: the faster, the better. Critical Care (2024).
2. Predicting Extended-Spectrum Beta-Lactamase and Carbapenem Resistance in Enterobacteriaceae Bacteremia: A Diagnostic Model Systematic Review and Meta-Analysis. Antibiotics (2023).
3. Modelling the implementation of narrow versus broader spectrum antibiotics in the empiric treatment of E. coli bacteraemia. Scientific Reports (2024).
4. Comparative analysis of a rapid diagnostic test and scoring tools for ESBL detection in Enterobacterales bloodstream infections for optimizing antimicrobial therapy. Microbiology Spectrum (2023).